Loading...
Market
What will be the percentage increase in Relay Therapeutics' stock (RLAY) by December 31, 2024?
3
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Stock market data from reputable financial news sources like Bloomberg or Yahoo Finance
Story
Relay Therapeutics' RLY-2608 Shows Positive Interim Data, Stock Rises 21.2%
Sep 9, 2024, 11:15 AM
Relay Therapeutics announced on Monday positive interim data for its experimental treatment, RLY-2608, which demonstrates clinically meaningful progression-free survival in patients with HR+/HER2- breast cancer. The early-stage study indicates that the combination treatment significantly extended the time patients lived without their disease worsening. Following the announcement, Relay Therapeutics' stock (RLAY) saw a pre-market increase of 21.2%. Dr. Don Bergstrom, President of R&D at Relay Therapeutics, highlighted the significance of these findings.
View original story
Similar markets
Yes • 50%
No • 50%
Increases by less than 10% • 25%
Increases by 10% to 25% • 25%
Increases by 25% to 50% • 25%
Increases by more than 50% • 25%
Yes • 50%
No • 50%
Decrease • 25%
Increase by less than 10% • 25%
Increase by 10% to 20% • 25%
Increase by more than 20% • 25%
Below $10 • 25%
$10 to $15 • 25%
$15 to $20 • 25%
Above $20 • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
